基于胎儿医学基金会早孕期风险探讨阿司匹林对子痫前期风险的影响
本研究为阿司匹林预防子痫前期试验的事后二次分析,按胎儿医学基金会早孕期风险分层评估阿司匹林效果。高依从性(≥90%)者中,阿司匹林150 mg与安慰剂相比降低任何孕周子痫前期(RR 0.64)、早产子痫前期(RR 0.24)和早期子痫前期(RR 0.06)。初始风险≥1/20者用阿司匹林后35周前子痫前期分娩为0.0%(安慰剂6.1%),但早产子痫前期未显著降低(RR 0.47)。
要点
- 高依从性者中阿司匹林150 mg降低任何孕周子痫前期(RR 0.64,95%CI 0.44-0.93)。
- 初始风险≥1/20者用阿司匹林后35周前子痫前期分娩0.0%,安慰剂组6.1%。
- 初始风险≥1/20者早产子痫前期未显著降低(RR 0.47,95%CI 0.17-1.34)。
核心结论
- 早孕期胎儿医学基金会早产子痫前期风险与子痫前期、早产子痫前期和早期子痫前期风险相关。
- 每日预防性使用150 mg阿司匹林且依从性≥90%时,初始风险<1/20者可预防几乎所有37周前子痫前期分娩,初始风险≥1/20(≥5%)者可预防几乎所有35周前子痫前期分娩。
- 初始风险≥1/20的妇女应从34至35周起密切监测,因其仍存在晚发型早产子痫前期风险。
研究设计与样本
- 阿司匹林预防子痫前期试验的事后二次分析,该试验将早孕期胎儿医学基金会算法评估的37周前子痫前期风险≥1/100(或1%)者随机分配至每日阿司匹林150 mg或安慰剂,从11至14周至36周。
- 安慰剂组822例按初始胎儿医学基金会风险计算子痫前期、早产子痫前期和早期子痫前期(34周前分娩)发生率。
- 高依从性(≥90%处方片剂)1143例按初始胎儿医学基金会风险评估阿司匹林效果,计算相对风险及95%置信区间。
主要发现
- 安慰剂组822例中,初始风险≥1/20(或>5%)者子痫前期总发生率21.7%、早产子痫前期8.4%、早期子痫前期6.4%,显著高于初始风险<1/20者(分别为8.1%、2.9%、0.3%;均P<.01)。
- 高依从性1143例中,阿司匹林与安慰剂相比降低任何孕周子痫前期(相对风险0.64,95%CI 0.44-0.93)、早产子痫前期(相对风险0.24,95%CI 0.09-0.63)和早期子痫前期(估计相对风险0.06,95%CI 0.01-0.96)。
- 初始风险≥1/20者中,阿司匹林组35周前子痫前期分娩为0.0%,安慰剂组为6.1%(估计相对风险0.06,95%CI 0.01-0.94);该亚组早产子痫前期未显著降低(相对风险0.47,95%CI 0.17-1.34)。
- 初始风险<1/20者中,阿司匹林组37周前子痫前期分娩为0例,安慰剂组为2.5%(估计相对风险0.05,95%CI 0.01-0.78)。
临床怎么用
- 作者结论指出,每日预防性使用150 mg阿司匹林且依从性≥90%时,初始风险<1/20者可预防几乎所有37周前子痫前期分娩,初始风险≥1/20(≥5%)者可预防几乎所有35周前子痫前期分娩。
- 作者结论指出,初始风险≥1/20的妇女应从34至35周起密切监测,因其仍存在晚发型早产子痫前期风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin reduces the risk of delivery with preterm preeclampsia among high-risk women, and such risk can be estimated in the first trimester of pregnancy using the Fetal Medicine Foundation algorithm by combining maternal factors with mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. It is unclear whether the initial risk influences the effect of aspirin. OBJECTIVE: This study aimed to estimate the effect of aspirin on preeclampsia according to first-trimester risk. STUDY DESIGN: This was a post hoc secondary analysis of the Aspirin for Evidence-Based Preeclampsia Prevention trial, which randomized participants with a first-trimester risk of preeclampsia with delivery before 37 weeks of gestation (preterm preeclampsia) of ≥1 in 100 (or 1%), based on the Fetal Medicine Foundation algorithm, to receive aspirin 150 mg or placebo daily from 11 to 14 weeks to 36 weeks of gestation. The rates of preeclampsia, preterm preeclampsia, and early preeclampsia (with delivery before 34 weeks of gestation) were calculated according to the initial Fetal Medicine Foundation risk. Among participants with high compliance (≥90% of tablets prescribed) based on regular tablet counts, the effect of aspirin was estimated according to the initial Fetal Medicine Foundation risk. Relative risks with 95% confidence intervals were calculated. RESULTS: Of 822 participants in the placebo group, those with an initial Fetal Medicine Foundation risk of ≥1 in 20 (or >5%) had an overall rate of preeclampsia (21.7%), preterm preeclampsia (8.4%), and early preeclampsia (6.4%) significantly greater than those with an initial risk of <1 in 20 (8.1%, 2.9%, and 0.3%, respectively; all with P<.01). Of 1143 participants with high compliance randomized to aspirin or placebo, aspirin was associated with a reduction in preeclampsia at any gestation (relative risk, 0.64 [95% confidence interval, 0.44-0.93]), preterm preeclampsia (relative risk, 0.24 [95% confidence interval, 0.09-0.63]), and early preeclampsia (estimated relative risk, 0.06 [95% confidence interval, 0.01-0.96]) compared with placebo. Subgroup analyses enabled the identification of a differential response according to the initial Fetal Medicine Foundation risk. Among participants with an initial risk of ≥1 in 20, an absence (0.0%) of delivery with preeclampsia up to 35 weeks of gestation was observed in those randomized to aspirin compared with 6.1% in those randomized to placebo (estimated relative risk, 0.06 [95% confidence interval, 0.01-0.94]). In addition, it was observed that aspirin did not reduce significantly the preterm preeclampsia in this subgroup (relative risk, 0.47 [95% confidence interval, 0.17-1.34]). In contrast, when the initial risk was <1 in 20, aspirin was associated with an absence of delivery with preeclampsia up to 37 weeks of gestation compared with 2.5% with placebo (estimated relative risk, 0.05 [95% confidence interval, 0.01-0.78]). CONCLUSION: The first-trimester Fetal Medicine Foundation risk of preterm preeclampsia is associated with the risks of preeclampsia, preterm preeclampsia, and early preeclampsia. The prophylactic daily use of 150 mg aspirin, with compliance of ≥90%, can prevent almost all cases of preeclampsia with delivery up to 37 weeks of gestation when the initial risk is <1 in 20 and up to 35 weeks of gestation when the initial risk is ≥1 in 20 (≥5%). Women with an initial risk of ≥1 in 20 should be closely monitored from 34 to 35 weeks of gestation as they remain at risk of late preterm preeclampsia.
引用
- Bujold E, Rolnik DL, Poon L, et al. The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk. Am J Obstet Gynecol. 2025. PMID: 41177290. doi:10.1016/j.ajog.2025.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。